Evan Kearns
Known title: Chief Legal OfficerCIK: 0001745285
Associated companies
Transaction History
| COGT | ▼ Sell | Open Market | 65,000 | $2.5M | 12/26/2025 | View on chart |
| COGT | ▼ Sell | Tax Withholding | 125,602 | $5.0M | 12/17/2025 | View on chart |
| COGT | ▲ Buy | Grant | 40,000 | $0 | 12/17/2025 | View on chart |
| COGT | ▲ Buy | Grant | 260,000 | $0 | 12/17/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cogent Biosciences: Long-term performance review published
Benzinga published an article analyzing the value of a $1,000 investment in Cogent Biosciences made five years ago. This piece focuses on historical returns rather than new corporate developments or immediate market catalysts. The stock is currently trading near its 52-week low, with technical indicators showing recent downward pressure.
Cogent Biosciences: Long-term performance review published. Benzinga published an article analyzing the value of a $1,000 investment in Cogent Biosciences made five years ago. This piece focuses on historical returns rather than new corporate developments or immediate market catalysts. The stock is currently trading near its 52-week low, with technical indicators showing recent downward pressure.